Douglas J. Swirsky
Chairman of the Board
Mr. Swirsky was appointed as a director of Cellectar in April 2017 and Chairman of the Board in August 2017. Since March 2023, Mr. Swirsky has served as Chief Financial Officer of MaxCyte, Inc. He has more than two decades of relevant experience in the biopharmaceutical and healthcare sectors, having served as a director of, or in senior management positions at, a number of publicly held companies over the last 17 years and having provided counsel to corporate clients as a healthcare investment banker.
Prior to MaxCyte, Mr. Swirsky served as Chief Financial Officer and Treasurer of AavantiBio, Inc. from February 2021 to December 2022. Prior to AavantiBio, he served as President, Chief Executive Officer and a director of Rexahn Pharmaceuticals from November 2018 to November 2020; having previously served as Rexahn’s President and Chief Financial Officer from January 2018 until his appointment as CEO. Prior to Rexahn, Mr. Swirsky served as President and Chief Executive Officer of GenVec, Inc., a clinical-stage biopharmaceutical company, from 2013 to 2017. From 2006 to 2013, Mr. Swirsky served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec. Prior to joining GenVec, Mr. Swirsky worked at Stifel Nicolaus, where he served as a managing director and the head of Life Sciences Investment Banking. Mr. Swirsky previously held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting.
Mr. Swirsky is a Certified Public Accountant and a CFA® charter-holder. He has been recognized as NACD Directorship Certified™ by the National Association of Corporate Directors. Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University.